Viatris (VTRS) Income towards Parent Company (2019 - 2026)
Viatris (VTRS) posted Income towards Parent Company of -$118.8 million for Q2 2026, down 167.35% on a QoQ basis from $176.4 million in Q1 2026, and down 2482.61% year-over-year from $5.0 million in Q2 2025.
Analysis
Viatris (VTRS) Income towards Parent Company (2019 - 2026) Analysis & Trends
Viatris has reported Income towards Parent Company for 8 years, with the latest figure at -$118.8 million in Q2 2026.
- On a quarterly basis, Income towards Parent Company fell 2482.61% year-over-year to -$118.8 million in Q2 2026; TTM through Jun 2026 was -$410.7 million, a 88.16% increase from a year earlier, with the FY2025 full-year figure at -$3.5 billion, down 454.23% from the prior year.
- Income towards Parent Company was -$118.8 million for Q2 2026 at Viatris, down from $176.4 million in the prior quarter.
- The five-year high for Income towards Parent Company was $1.0 billion in Q4 2022, with the low at -$3.0 billion in Q1 2025.
- Average Income towards Parent Company over 5 years is -$108.8 million, with a median of $104.4 million recorded in 2024.
- The sharpest annual moves came in 2022 and 2025: Income towards Parent Company surged 483.32% in 2022, then sank 2770.76% in 2025.
- Over 5 years, Income towards Parent Company stood at $1.0 billion in 2022, then tumbled by 175.71% to -$765.6 million in 2023, then soared by 32.54% to -$516.5 million in 2024, then surged by 34.15% to -$340.1 million in 2025, then soared by 65.07% to -$118.8 million in 2026.
- The last three Income towards Parent Company figures came in at -$118.8 million (Q2 2026), $176.4 million (Q1 2026), and -$340.1 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.63 Bn | 38.97 Bn | 2.15 Bn |
| 2 | Viatris | 19.19 Bn | 18.30 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.48 Bn | 5.35 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.36 Bn | 520.30 Mn | 2.10 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn |
| 8 | Amphastar Pharmaceuticals | 995.52 Mn | 705.40 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 404.35 Mn | 363.10 Mn | 17.15 Mn |
| 10 | RedHill Biopharma | 176.59 Mn | 176.59 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -118.80 Mn |
| Mar 31, 2026 | 176.40 Mn |
| Dec 31, 2025 | -340.10 Mn |
| Sep 30, 2025 | -128.20 Mn |
| Jun 30, 2025 | -4.60 Mn |
| Mar 31, 2025 | -3.04 Bn |
| Dec 31, 2024 | -516.50 Mn |
| Sep 30, 2024 | 94.80 Mn |
| Jun 30, 2024 | -326.40 Mn |
| Mar 31, 2024 | 113.90 Mn |
| Dec 31, 2023 | -765.60 Mn |
| Sep 30, 2023 | 331.60 Mn |
| Jun 30, 2023 | 264.00 Mn |
| Mar 31, 2023 | 224.70 Mn |
| Dec 31, 2022 | 1.01 Bn |
| Sep 30, 2022 | 354.30 Mn |
| Jun 30, 2022 | 313.90 Mn |
| Mar 31, 2022 | 399.20 Mn |
| Dec 31, 2021 | -263.80 Mn |
| Sep 30, 2021 | 311.50 Mn |